For research use only. Not for therapeutic Use.
VU534 is a NAPE-PLD activator, with an EC50 of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC50 of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study [1] .
VU534 (up to 30 μM, 24 h) shows minimal cytotoxicity in HepG2 and Raw264.7 cell lines [1].
VU534 (3-30 μM, 1 h) increases NAPE-PLD activity in Raw264.7 cells [1].
VU534 (1 h) increases NAPE-PLD activity in HepG2 cells, with the EC50 values of 1.5 μM[1].
VU534 (5 μM, 1 h) increases NAPE-PLD activity 1.5-fold, but not reverses LEI-401(HY-131181)-inhibited NAPE-PLD activity [1].
VU534 (10 μM, 6 h) significantly enhances efferocytosis in bone-marrow-derived macrophages, but not work in Napepld-/- KO[1].
| Catalog Number | I040879 |
| CAS Number | 923509-20-0 |
| Synonyms | N-(5,7-dimethyl-1,3-benzothiazol-2-yl)-1-(4-fluorophenyl)sulfonylpiperidine-4-carboxamide |
| Molecular Formula | C21H22FN3O3S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H22FN3O3S2/c1-13-11-14(2)19-18(12-13)23-21(29-19)24-20(26)15-7-9-25(10-8-15)30(27,28)17-5-3-16(22)4-6-17/h3-6,11-12,15H,7-10H2,1-2H3,(H,23,24,26) |
| InChIKey | RLHUIVPGYWWIQZ-UHFFFAOYSA-N |
| SMILES | CC1=CC(=C2C(=C1)N=C(S2)NC(=O)C3CCN(CC3)S(=O)(=O)C4=CC=C(C=C4)F)C |
| Reference | [1]. Jonah E Zarrow, et al. Small Molecule Activation of NAPE-PLD Enhances Efferocytosis by Macrophages. ACS Chem. Biol. 2023, 18, 8, 1891–1904. |
